Neurological safety of fingolimod: An updated review

Fingolimod (FTY) is the first oral medication approved for treatment of relapsing–remitting multiple sclerosis (RRMS). Its effectiveness and safety were confirmed in several phase III clinical trials, but proper evaluation of safety in the real patient population requires long‐term post‐marketing mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshii, Fumihito, Moriya, Yusuke, Ohnuki, Tomohide, Ryo, Masafuchi, Takahashi, Wakoh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
MS/NMO and allied disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575715/
https://www.ncbi.nlm.nih.gov/pubmed/28932291
http://dx.doi.org/10.1111/cen3.12397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575715/
https://www.ncbi.nlm.nih.gov/pubmed/28932291
http://dx.doi.org/10.1111/cen3.12397

Ejemplares similares